Drug Profile
Research programme: mineralocorticoid receptor antagonists - Karo Pharma
Latest Information Update: 08 Jan 2022
Price :
$50
*
At a glance
- Originator Karo Bio
- Class
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 23 Oct 2003 Karo Bio has made significant progress in solving the receptor structure of the hormone-binding domain in complex with the natural hormone aldosterone
- 23 May 2001 Preclinical development for Congestive heart failure in Sweden (Unknown route)
- 23 May 2001 Preclinical development for Hypertension in Sweden (Unknown route)